Fair Value Measurements - Additional Information (Detail) (USD $)	9 Months Ended						1 Months Ended	9 Months Ended
	Jun. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2014 2010 Warrants	Jun. 30, 2014 2012 Warrants	Jun. 30, 2014 2013 Warrants	Jan. 31, 2011 Unidym Inc	Jun. 30, 2014 Ablaris Therapeutics
Fair Value Measurements Disclosure [Line Items]
Short term investments	$ 23,834,408	$ 9,030,261
Investments	26,284,862	1,702,153
Total investments	50,119,270	10,732,414
Fair value of investments	49,735,616	10,698,271
Non cash consideration received in sale of interest in subsidiary, bonds							2,500,000
Bond convertible conversion price per share							$ 2.00
Warrants issued to acquire Common Stock				329,649	912,543	833,530
Warrants outstanding	1,526,781			24,324	265,161	24,623
Non-cash gain (loss) from change in fair value of the derivative liability	5,680,544							31,791
Duration of exchange rights								7 years
Exchange right convertible conversion ratio for first year								0.06
Exchange right convertible conversion ratio for second year								0.04
Exchange right convertible conversion ratio for third year								0.03
Exchange right convertible conversion ratio for fourth year								0.02
Exchange right convertible conversion ratio for fifth year and beyond								0.01
Number of exchange right sold								675,000
Business combination, contingent consideration	$ 1,595,273	$ 1,595,273	$ 173,621